Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Grammy Award-winner Bruce Hornsby will ... philanthropists, athletes, actors, and musicians during the 10 th ... at the Mandarin Oriental Hotel in New ... honor six individuals who embody the values of the ... its highest honor, the Spirit of an Active Lifestyle ...
(Date:10/31/2014)... Imago BioSciences, Inc., a biotech company ... Series A financing led by Clarus Ventures LLC, ... of accomplished investment and operating professionals dedicated to ... include Frazier Healthcare, Amgen Ventures, and Merck Research ... Frazier Healthcare will join the company,s board of ...
(Date:10/31/2014)... Investor-Edge has initiated coverage on ... ), Isis Pharmaceuticals Inc. (NASDAQ: ISIS ), ... Pharmaceuticals Inc. (NASDAQ: ACAD ), and Synta ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,566.14, up 0.37%, the Dow Jones Industrial ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a ... extracellular matrix , today announced it plans to report ... 2011 before the open of the financial markets. The ... the investment community at 8:00 a.m. PDT (11:00 a.m. ...
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader ... and infectious diseases, announced today that the company will make ... Research Conference San Francisco, CA, May 9-11, 2011 The ... Dr. J. Joseph Kim, Ph.D., President & CEO May 9, ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:10/31/2014)... Chico, CA. (PRWEB) October 31, 2014 ... best known for its small scale BioPro™ biodiesel ... equipment that will further improve the performance and ... , The GL95/MC12/BD380 trio will recover ... is mixed in with the glycerin by-product produced ...
(Date:10/31/2014)... Research Center for Healthy Neighborhoods (PRCHN) at Case ... key player in nearly $13.32 million in federal ... Ohio. , The Centers for Disease Control and ... million over five years. The funds will support ... disseminating individual, environmental, and policy interventions that prevent ...
(Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 The Memory ... was created by Alexander Lynch, whose father suffered from Alzheimer's ... a dramatic moment, caused by his father's disease. His father ... That was the crucial moment when the author of this ... his dad. , The Memory Healer program is based ...
(Date:10/31/2014)... 2014 Monica Williams-Murphy MD , ... too well the chaos that can occur for people ... vast majority of Americans who come into the emergency ... completely unprepared for the moment and so are their ... serve as a catalyst for a family to get ...
(Date:10/31/2014)... Summit, Missouri (PRWEB) October 31, 2014 ... the country about families narrowly escaping carbon monoxide poisoning ... season) looms just weeks away, one family-owned, Missouri-based heating ... straightforward approach to making sure families start the home ... are safe and secure. , Beginning Nov. 1, ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3
... at the Imperial College London it was found that lab ... , It was believed that early exposure to ... lab workers who frequently handled research rodents had fewer allergic ... to be protective against eczema allergy. The study results are ...
... a stroke, caused either by a blocked or burst blood vessel ... die. ,That's the bad news. ,And the good news! ... problems that cause many strokes — before a stroke ever happens. ... the skull. ,New technologies, delivered to the brain via ...
... who is now 42 years old has been slightly unconscious and ... His nerves were completely sheared in a car crash and he ... others by means of grunts and nods. But now his speech ... the tiny nerve connections in his brain slowly started to rewire. ...
... conducted by the Korean scientists from the Korea Research Institute of ... that the research team has found a human gene that aids ... The researchers were very happy about the discovery and said that ... cancers. ,The study was mainly conducted on mice and ...
... Haryana Government has decided to start a two year ... in Panchakarma at Shri Krishna Government// Ayurvedic College at ... diploma courses has already been formulated and these courses ... state Health Minister Kartar Devi told reporters here., ...
... to be far from the goal of any reversal of the ... in cases of drug abuse in all of Europe//. The statistics ... abuse category and a rank 3 in cocaine and ecstasy abuse. ... abuse. ,As per the drug policy of the government, ...
Cached Medicine News:Health News:Brain Surgery Without the Surgery? 2Health News:Brain Surgery Without the Surgery? 3Health News:Brain Surgery Without the Surgery? 4Health News:Brain Surgery Without the Surgery? 5Health News:Brain Surgery Without the Surgery? 6
... SAFE-T-FILL Capillary Blood Collection Tubes are 100% ... a wide range of applications, the Capillary ... tube, attached cap and a micro tube.,The ... the blood into the micro tube thereby ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
... The Bio-Rad Mumps IgG test is an ... Test results are obtained after a 90-minute incubation. ... index values, permitting uniformity of reporting. The ... qualitative and semi-quantitative detection of human IgG antibodies ...
... Bio-Rad Measles IgG test is an enzyme immunoassay ... are obtained after a 90-minute incubation. The ... permitting uniformity of results. The Bio-Rad Measles ... semi-quantitative detection of human IgG antibodies to measles ...
Medicine Products: